Curis is a biotechnology company focused on the development of first-in-class and innovative therapeutics for cancer, with a pipeline of differentiated small molecule hematology and oncology drug candiates. Currently Curis has two drugs candidates in development; CA-4948 an oraly available small molecule inhibitor of IRAK4 kinase in non-Hodgkin's lymphoma and leukemia (AML/MDS), and CI-8993 a clinical-stage human IgG1 kappa monoclonal antibody designed to antagonize the VISTA signaling pathway in advance solid tumors.
Curis is a biotechnology company focused on the development of first-in-class and innovative therapeutics for the treatment of cancer. We are focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies. Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study, both as a monotherapy and in combination with the BTK inhibitor ibrutinib, and the Phase 1/2 TakeAim Leukemia study (AML and hrMDS)